Clinical Trials
9 trialsNCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
NCT03764293 2024-02-06
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT03396211 2023-04-07
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Phase 1 Completed
NCT01192971 2023-03-03
HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01497704 2017-10-02
Dose-Escalation and Safety Trial of YN968D1
Elevar Therapeutics
Phase 1/2 Completed
NCT02836171 2017-02-27
Effect of Itraconazole on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02836821 2017-02-27
Effect of Rifampicin on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT00633490 2008-07-22
Study of Apatinib as an Inhibitor of Tumor Angiogenesis
Fudan University
Phase 1 Unknown